CIDRAP newsletters options
Three COVID-19 vaccine doses offer good protection against infection and hospitalization, including those caused by variants of concern—regardless of brand, type, or combination, according to an ongoing meta-analysis published yesterday in BMJ.
The findings reveal substantial global collateral damage during the pandemic.
In the US, the more transmissible BA.2.12.1 subvariant now makes up nearly 60% of sequenced samples.
"There's a window of opportunity where this can be contained," a WHO official says.
About 75% of COVID-19 deaths in the least-vaccinated Chicago areas could have been prevented if their uptake would have equaled that of the highest-coverage areas during the Alpha and Delta variant surges, suggests a study late last week in JAMA Network Open.
The World Health Assembly (WHA) last week passed a resolution that aims to make infection prevention and control (IPC) a critical element of addressing healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) and of preparing for infectious disease health emergencies.
More than 20 countries have logged a combined total of more than 300 monkeypox cases.
"Seeing the numbers really does crystallize the urgency of this issue."
Long COVID can affect even fully vaccinated people after mild breakthrough infections.
Report characterizes risks in the 100-day supply chains of 143 essential prescription drugs.
International survey finds 62% reported 1 or more symptoms of burnout, and 31% reported 2.
Yesterday the US Department of Agriculture's National Institute of Food and Agriculture (USDA NIFA) announced an investment of more than $5 million, spread across nine projects, to mitigate antimicrobial resistance (AMR) across the food chain.
Symptomatic COVID-19 cases are responsible for more viral transmission than asymptomatic infections, suggests an updated systematic review and meta-analysis of 130 studies published yesterday in PLOS Medicine.
Weekly prescriptions for oral COVID-19 antivirals rose from about 27,000 to more than 182,000 in 7 weeks.
"The risk of exposure is not limited to any one particular group," CDC director says, adding that the disease doesn't care about borders.
A letter yesterday in the New England Journal of Medicine (NEJM) from Centers for Disease Control and Prevention scientists shows homologous (same-vaccine) boosting for Johnson & Johnson (J&J) vaccine recipients was significantly less effective than mix-and-match booster doses when the Omicron strain was predominant in the United States.
Though given to only 1 patient, tecovirimat was tied to a shorter illness and signs of shorter viral shedding.
Two global regions that saw recent increases in infections are now seeing downturns, but the US reports the most new cases and deaths.
Cases in Europe have risen to 118, and the UK has now confirmed 78 monkeypox infections.
